Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board Read More » November 25, 2024
Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity Read More » August 13, 2024
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding Read More » May 8, 2024
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. Read More » April 17, 2024
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases Read More » February 27, 2024
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study Read More » November 28, 2023
Derm-Biome Pharmaceuticals to Present at the 2023 OBIO Investment Summit on February 10, 2023 Read More » February 7, 2023
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne Read More » January 10, 2023
Derm-Biome Pharmaceuticals, Inc. reports Positive Results from a Preclinical Study in Atopic Dermatitis: its new generation of compounds are significantly more effective than FDA-approved topical AD drug crisaborole Read More » September 16, 2021
Derm-Biome Pharmaceuticals, Inc. files a US provisional patent for a new generation of natural product-based derivatives and their uses for treating chronic inflammatory skin conditions Read More » June 28, 2021
Derm-Biome Pharmaceuticals, Inc. adds skin disease and microbiome specialists Drs. Youwen Zhou and Andy Sham to Its Newly Created Scientific Advisory Board Read More » June 21, 2021
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis Read More » October 6, 2020
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases Read More » July 2, 2020
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis Read More » March 23, 2020
Skin health startup Derm-Biome Pharmaceuticals, Inc. to receive funding from the Government of Canada Read More » July 9, 2019
Derm-Biome Pharmaceuticals Inc Seeks Collaborators To Test Promising Anti-Tumor Compound On Skin Cancer In Dogs Cats And Horses. Read More » March 20, 2019
Derm-Biome Pharmaceuticals Inc. announces an exciting collaboration with Harvard Medical School Read More » February 22, 2019
Derm-Biome Pharmaceuticals Inc. commences testing its proprietary compounds on skin microbiome targets. Read More » October 26, 2018
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Read More » December 1, 2008